ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Two new TB drugs advance to clinic

TBA-7371 and sutezolid begin Phase I studies

by Lisa M. Jarvis
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

Two new drugs for tuberculosis are being tested in humans, an important step in addressing the dearth of treatments for the deadly infection. The nonprofit TB Alliance says Phase I studies have started for both TBA-7371, part of a new class of antimicrobials called DprE1 inhibitors, and the oxazolidinone sutezolid.

TBA-7371 blocks an enzyme critical for synthesizing the polysaccharides that compose the TB bacteria’s cell wall. Development of DprE1 inhibitors began as part of a research collaboration between TB Alliance and AstraZeneca. In 2014, AstraZeneca shut down the R&D site in Bangalore, India, where TB work was conducted, and the nonprofit continued to pursue the compound class.

Sutezolid, meanwhile, has been around since the late 1990s. The compound is an analog of the approved antibiotic linezolid, but with fewer side effects and better potency.

The trials are “definitely a step forward,” says Sean Ekins, who is CEO of Collaborations Pharmaceuticals and is on the advisory board of the TB-focused nonprofit MM4TB. Ekins points out that most combination treatments in clinical studies rely on drugs that were invented in the 1940s and ’50s. “The pipeline is so sparse that anything going into a clinical trial is huge.”

Indeed, just two other new TB drugs have been approved in recent years, and both—Johnson & Johnson’s bedaquiline and Otsuka Pharmaceutical’s delamanid—are intended only to treat multi-drug-resistant TB.

Yet the need for new TB treatments is great. The World Health Organization estimates that 2 billion people are infected with the bacteria that cause TB and that the infection kills some 1.8 million people each year. The threat has become particularly worrisome for those with compromised immune systems; in 2015, 400,000 people coinfected with TB and HIV died.

X

Article:

This article has been sent to the following recipient:

Comments
C Kannan Janakiraman (October 23, 2017 10:48 AM)
The introduction of the two new molecules is encouraging and reflects a definite step forward towards the 2024 objective of establishing POC for a shorter duration (1 month) therapy. However, there is urgent need for consideration of the following facts and objectives. 1.Targeting the disease from the point of latent infection (hidden within the granulomas), 2.enhancing host immune system with help of proven adjuvant therapies,3. Rational study designs for clinical development by early inclusion of adjuvant therapies to eradicate the infection via multiple mechanisms facilitating pathogen load reduction in a shorter duration. 4. integration of the clinical development with efficient diagnostic and treatment monitoring tools and biomarkers, 5.pinpoint diagnosis and treatment of extrapulmonary infection across the population and particularly in those with immunocompromised conditions associated with other non communicable diseases (like metabolic syndrome, Diabetes, NAFLD etc).

Leave A Comment

*Required to comment